A Pivotal Trial of ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Phase of Trial: Phase III
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Derazantinib (Primary)
- Indications Cholangiocarcinoma
- Focus Registrational; Therapeutic Use
- Sponsors ArQule
- 24 Jul 2017 Status changed from planning to recruiting.
- 15 Mar 2017 New trial record
- 07 Mar 2017 According to an ArQule media release, company plans to initiate this trial in Q3 of 2017.